Thus, ONECUT3, identified as a regulator of the Warburg effect in CRC in this study, maybe a promising candidate for combination with immunotherapy to improve its effectiveness and address existing challenges in treating CRC. Here, ONECUT3 is linked to colorectal carcinoma.